Results 81 to 90 of about 3,781 (191)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis

Emerging Infectious Diseases, 2017
We report the experiences of 5 patients taking bedaquiline with delamanid in combination: 1 patient was cured; 3 culture converted, with 2 continuing and 1 changing therapy; and 1 died from respiratory insufficiency.
Andrey Maryandyshev, Emanuele Pontali, Simon Tiberi, Onno Akkerman, Shashank Ganatra, Tsetan Dorji Sadutshang, Jan-Willem Alffenaar, Rohit Amale, Jai Mullerpattan, Sonam Topgyal, Zarir Farokh Udwadia, Rosella Centis, Lia D’Ambrosio, Giovanni Sotgiu, Giovanni Battista Migliori   +14 more
doaj   +1 more source

Black Hairy Tongue as a Rare Adverse Effect of Linezolid in Multidrug‐Resistant Tuberculosis: A Case Report

Clinical Case Reports, Volume 13, Issue 9, September 2025.
ABSTRACT Black hairy tongue (BHT), or lingua villosa nigra, is a rare adverse effect of linezolid, an antibiotic frequently used in the treatment of multidrug‐resistant tuberculosis (MDR‐TB). We present a case of a 24‐year‐old female who developed BHT while receiving linezolid as part of a longer regimen for MDR‐TB.
Dipendra Adhikari, Salina Paudel, Munna William, Manoj Kumar Bhatt, Sanju Dahal, Abishkar Gautam, Binay Adhikari   +6 more
wiley   +1 more source

Effect of delamanid on interim outcomes of bacteriological conversion amongst pediatric drug resistant tuberculosis cases in India

Lung India
Aim: To determine the bacteriological conversion rate after 6 months of Delamanid (DLM) based treatment in children with drug-resistant tuberculosis (DR-TB) and determine factors associated with bacteriological conversion.
Dhruv Kalawadia, Darshini Gandhi, Tsering Y Dirkhipa, Akanksha Jaiswal, Daksha Shah, Jyoti Salve, Malik Parmar, Kuldeep S Sachdeva, Minnie Bodhanwala, Ira Shah   +9 more
doaj   +1 more source

Delamanid expanded access novel treatment of drug resistant tuberculosis [Corrigendum]

, 2015
Rustomjee R, Zumla A. Delamanid expanded access novel treatment of drug resistant tuberculosis. Infection and Drug Resistance. 2015;8:359–366. Dr Rustomjee and Professor Zumla are grateful to a reader for raising some issues regarding ...
Zumla A, Rustomjee R
core  

Delamanid expanded access novel treatment of drug resistant tuberculosis

Infection and Drug Resistance, 2015
Roxana Rustomjee,1 Alimuddin Zumla2,31South African Medical Research Council, Cape Town, South Africa; 2Division of Infection and Immunity, University College London, London, UK; 3NIHR Biomedical Research Centre, University College Hospitals NHS ...
Rustomjee R, Zumla A
doaj  

Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea

, 2017
Objectives: Delamanid is a new anti-TB drug, but few data exist on its use outside clinical trials. The purpose of this study was to evaluate the efficacy as well as the safety and tolerability of a delamanid-containing regimen for 24 weeks in the ...
Won-Jung Koh, Mok, Jeongha, Doosoo Jeon, Park, Jin Su, Soo Hee Hwang, Bohyoung Kang, Jin Su Park, Jeongha Mok, Hyungseok Kang, Hwang, Soo Hee, Jeon, Doosoo, Jae-Joon Yim, Lee, Taehoon, Yim, Jae-Joon, Taehoon Lee, Kang, Hyungseok, Kang, Bohyoung, Koh, Won-Jung   +17 more
core   +1 more source

Effect of adding delamanid to a regimen composed of three drugs likely to be effective, endTB observational cohort (N = 362).

, 2023
Effect of adding delamanid to a regimen composed of three drugs likely to be effective, endTB observational cohort (N = 362).
Zaw Myint (6166169), Samreen Sarfaraz (10884833), Kwonjune J. Seung (15374272), Stalz Charles Vilbrun (15374290), Sara Lodi (462540), Carole D. Mitnick (8385144), Michael Rich (363365), Munara Gulanbaeva (15374308), Jay Achar (3405698), Palwasha Khan (771358), Saman Ahmed (15374296), Mathieu Bastard (109538), Marika Gergedava (15374311), Catherine Hewison (7293095), Elena Algozhina (15374299), Carly A. Rodriguez (2805904), Stephanie Mpinda (15374281), Naseem Salahuddin (496353), Kalkidan Yae (15374293), Cut Yulia Indah Sari (15374314), Nara Melikyan (15374278), Ofelya Petrosyan (15374287), Sara de Guadelupe Perea Moreno (15374305), Yugandran Naidoo (15374284), Jude Beauchamp (15374302), Helena Huerga (109527), Uzma Khan (583489), Sidney Atwood (496123), Molly F. Franke (7372517), C. Robert Horsburgh (7512506), Md Manzur-ul-Alam (15374275)   +30 more
core   +1 more source

Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance Mycobacterium tuberculosis in Shanghai, China

Infection and Drug Resistance, 2023
Yinjuan Guo,1 Jinghui Yang,1 Weiping Wang,1 Xiaocui Wu,1 Baoshan Wan,1 Hongxiu Wang,1 Wei Sha,2 Fangyou Yu1 1Department of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of China ...
Guo Y, Yang J, Wang W, Wu X, Wan B, Wang H, Sha W, Yu F   +7 more
doaj  

CRISPR Screening and Comparative LC‐MS Analysis Identify Genes Mediating Efficacy of Delamanid and Pretomanid against Mycobacterium tuberculosis

Advanced Science
Tuberculosis (TB), the leading cause of death from bacterial infections worldwide, results from infection with Mycobacterium tuberculosis (Mtb). The antitubercular agents delamanid (DLM) and pretomanid (PMD) are nitroimidazole prodrugs that require ...
Mei‐Yi Yan, Haifeng Li, Yun‐Mo Qu, Si‐Shang Li, Dandan Zheng, Xiao‐Peng Guo, Zhaojun Wu, Jie Lu, Yu Pang, Weimin Li, Jian Yang, Lingjun Zhan, Yi‐Cheng Sun   +12 more
doaj   +1 more source

Delamanid for the treatment of patients with resistant tuberculosis [PDF]

, 2019
El objetivo es evaluar la eficacia y seguridad, así como documentos relacionados a la decisión de cobertura del delamanid para tuberculosis ...
Calderón Cahua, María
core